CHRS

시간 외 거래: 1.10 0.06 +5.77%

Coherus Biosciences Inc (CHRS)

Relative Volume:

Coherus Biosciences Inc Stock (CHRS) Company Profile

Coherus Biosciences Inc

(650) 649-3530

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

최신 SEC 제출 서류

CHRS's Discussions on Twitter

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-07-24	개시	Citigroup	Buy
2023-05-01	개시	Truist	Buy
2023-03-28	업그레이드	UBS	Neutral → Buy
2022-06-14	개시	UBS	Neutral
2022-03-07	다운그레이드	JP Morgan	Overweight → Neutral
2020-07-16	개시	BofA Securities	Neutral
2020-04-17	개시	SunTrust	Buy
2019-08-13	개시	Mizuho	Buy
2019-08-02	재확인	H.C. Wainwright	Buy
2019-08-02	재확인	Maxim Group	Buy
2019-06-11	개시	Barclays	Overweight
2019-05-07	개시	H.C. Wainwright	Buy
2018-08-28	개시	H.C. Wainwright	Buy
2018-03-09	재확인	Maxim Group	Buy
2017-08-08	재확인	JP Morgan	Overweight
2017-06-13	재확인	Maxim Group	Buy
2017-05-05	개시	BMO Capital Markets	Outperform
2016-10-19	개시	Robert W. Baird	Outperform
2016-09-07	개시	Maxim Group	Buy
2016-07-27	개시	Citigroup	Buy
2016-01-20	개시	Credit Suisse	Outperform

Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스

Coherus Biosciences Inc (CHRS) 재무 분석

Coherus Biosciences Inc (CHRS)

Coherus Biosciences Inc Stock (CHRS) Company Profile

Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades

Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스

Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now - Yahoo Finance

Wall Street SWOT: Coherus Biosciences stock faces headwinds amid market challenges - Investing.com

Junshi wins European approval for cheaper checkpoint blocker - The Pharma Letter

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Insider Monkey

Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges - Yahoo Finance

CHRS stock touches 52-week low at $1.01 amid market challenges - Investing.com India

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive - Simply Wall St

CHRS (Coherus BioSciences) Debt-to-EBITDA : -10.54 (As of Jun. 2024) - GuruFocus.com

Institutional owners may take dramatic actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) recent 12% drop adds to one-year losses - Yahoo Finance

Coherus BioSciences (CHRS) Stock Price, News & Analysis - MarketBeat

HC Wainwright Weighs in on Coherus BioSciences, Inc.'s FY2028 Earnings (NASDAQ:CHRS) - MarketBeat

Coherus shares stumble on supply issue - The Pharma Letter

HC Wainwright Comments on Coherus BioSciences, Inc.'s FY2024 Earnings (NASDAQ:CHRS) - MarketBeat

Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Australia

Coherus BioSciences, Inc. (NASDAQ:CHRS) Has Found A Path To Profitability - Simply Wall St

Baird maintains Coherus outperform stock rating on recent supply hiccup By Investing.com - Investing.com Canada

Baird maintains Coherus outperform stock rating on recent supply hiccup - Investing.com

Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright - MarketBeat

Coherus BioSciences faces UDENYCA supply disruption - Investing.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Downgraded to "Hold" at StockNews.com - MarketBeat

Coherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 6.0% in August - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Upgraded to Buy by StockNews.com - MarketBeat

CHRS (Coherus BioSciences) Enterprise Value : $254.6 Mil (As of Aug. 19, 2024) - GuruFocus.com

CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com

CHRS stock touches 52-week low at $1.22 amid market challenges - Investing.com UK

CHRS (Coherus BioSciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com

UBS Downgrades Coherus BioSciences (CHRS) - MSN

UBS cuts Coherus to neutral, cites limited growth opportunities - MSN

Coherus BioSciences (NASDAQ:CHRS) Stock Rating Lowered by UBS Group - MarketBeat

Coherus BioSciences (NASDAQ:CHRS) Downgraded by UBS Group - Defense World

UBS cuts Coherus shares target amid concerns over future revenue growth - Investing.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Evaluating Coherus BioSciences: UDENYCA’s Sucess And LOQTORZI’s Prospects (NASDAQ:CHRS) - Seeking Alpha

Vanguard Group Inc. Has $24.09 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World

Coherus BioSciences Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript - Seeking Alpha

Coherus BioSciences: Q2 Earnings Snapshot - CTPost

A quintet of CFO hires at Intra-Cellular, Engrail, Faron, Coherus and Element - BioCentury

Coherus BioSciences: Q2 Earnings Snapshot - Houston Chronicle

Coherus BioSciences: Q2 Earnings Snapshot - San Antonio Express-News

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - MSN

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Finance

Coherus Biosciences Appoints Bryan McMichael as CFO - TipRanks

Coherus BioSciences: Q2 Earnings Snapshot - The Bakersfield Californian

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S - Simply Wall St

Coherus BioSciences (CHRS) to Release Earnings on Thursday - Defense World

Coherus Biosciences Inc (CHRS) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CHRS과 유사한 종목